MedTrace Logo

HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)

NCT06631326 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 244

Last updated 2026-01-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with high tumor burden advanced-stage hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).

Conditions

  • HCC - Hepatocellular Carcinoma
  • Hepatic Arterial Infusion Chemotherapy
  • BCLC Stage C Hepatocellular Carcinoma
  • Lenvatinib
  • PD-1 Inhibitors

Interventions

PROCEDURE

hepatic artery infusion chemotherapy

Hepatic arterial infusion chemotherapy including FOLFOX and RALOX

DRUG

Lenvatinib + PD-1 monoclonal antibody

PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab

Sponsors & Collaborators

  • First Hospital of China Medical University

    lead OTHER

Principal Investigators

  • Haibo Shao · First Hospital of China Medical University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2025-10-22
Completion
2025-10-22

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06631326 on ClinicalTrials.gov